Xention Limited

Japan Tobacco Inc.

Ucl Business Plc

Ark Therapeutics Limited

Arktherapeutics Group, Plc

Basil Hartzoulakis

David John Madge

Derek Edward John

Mushtaq Mulla

Richard John Hamlyn

John Ford

David Lawrence Selwood

Simon James Jones

Sasha Louise Garrett

Ian Zachary

Chris Chapman

Haiyan Jia

Ashley Jarvis

Simon Mark Jones

Oliver Gareth Dugdale

Michelle Tickner

Lili Cheng

Katie Ellard

Rosemary Lynch

Jamie Nally

Mark Stewart

Simon David Edwards

Helen Jane Payne

James Mitchell Leiper

Richard Blunt

Sharon Rossiter

Patrick John Thompson Vallance

Fiona Chan

Derek Roland Pollard

Lindsay Brown

David Madge

Patrick John Vallance

Helen Payne

The present invention provides a compound of formula (I) or its salts or pharmaceutically acceptable derivatives thereof wherein X, R, R, R, R, and Rare defined as set forth in the specification. The compounds are useful as potassium ion channel inhibitors.

Potassium channel blockers

The present invention provides compounds of formula (I): (Formula (I); wherein A, R, R, R, V, X, and Z are defined herein, which are potassium channel inhibitors. The invention further provides pharmaceutical compositions comprising the compounds of formula (I) and their use in therapy, in particular in treatment of diseases or conditions that are mediated by K3.1 and/or K3.4 or any heteromultimers thereof, or that require inhibition of K3.1 and/or K3.4 or any heteromultimers thereof.

Thieno-pyrimidines, useful as potassium channel inhibitors

Compounds

A compound of formula (I)  Or its salts or pharmaceutically acceptable derivatives thereof wherein; 

The present invention provides a compound of formula (I) or its salts or pharmaceutically acceptable derivatives thereof, wherein R, R, R, R, R, X, and j are defined herein. The compounds are useful as potassium ion channel inhibitors.

The present invention provides a compound of formula (I) or its salts or pharmaceutically acceptable derivatives wherein R, R, R, X, and A are defined herein. The compounds are useful as potassium ion channel inhibitors.

The present invention is a compound of formula (I) or formula (II) which are suitable as NP-1 antagonists.

Arginine derivatives with NP-1 antagonistic activity

The present invention is a compound of formula (I) or formula (II) which are suitable as NP-1 antagonists. 

Arginine derivatives with NP-I antagonistic activity

Compounds of formula (I) have been found to be useful as inhibitors of DDAH. The present invention thus provides the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of a disease whose pathology is affected by DDAH 

Guanidine derivatives as inhibitors of DDAH

Growing community of inventors

Cambridge, United Kingdom

Basil Hartzoulakis